Cargando…
THER-02. IMPACT OF SYSTEMIC THERAPY IN MELANOMA BRAIN METASTASIS
BACKGROUND: Melanoma brain metastasis is associated with a median overall survival (OS) of approximately 9 months. In recent years, management of melanoma brain metastases (MBM) by surgery and radiation [stereotactic radiosurgery (SRS) and whole brain radiation therapy (WBRT)] has been bolstered by...
Autores principales: | Sagar, Soumya, Lauko, Adam, Barnett, Addison, Wei, Wei, Chao, Samuel, Peereboom, David, Stevens, Glen, Angelov, Lilyana, Yu, Jennifer, Murphy, Erin, Mohammadi, Alireza, Suh, John, Barnett, Gene, Ahluwalia, Manmeet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213196/ http://dx.doi.org/10.1093/noajnl/vdz014.045 |
Ejemplares similares
-
THER-10. IMPACT OF BRAF MUTATIONAL STATUS ON THE EFFICACY OF IMMUNOTHERAPY FOR MELANOMA BRAIN METASTASES
por: Lauko, Adam, et al.
Publicado: (2019) -
THER-13. IMMUNOTHERAPY VERSUS STANDARD OF CARE IN MELANOMA BRAIN METASTASES WITH KNOWN BRAF STATUS
por: Barnett, Addison, et al.
Publicado: (2019) -
THER-16. EFFICACY OF UPFRONT IMMUNE CHECKPOINT INHIBITORS IN LUNG CANCER BRAIN METASTASIS
por: Barnett, Addison, et al.
Publicado: (2019) -
THER-09. IMPACT OF KRAS MUTATION STATUS ON THE EFFICACY OF IMMUNOTHERAPY IN LUNG CANCER BRAIN METASTASES
por: Lauko, Adam, et al.
Publicado: (2019) -
THER-14. INFLUENCE OF CLINICAL PARAMETERS ON THE EFFICACY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER BRAIN METASTASES (NSCLCBM)
por: Lauko, Adam, et al.
Publicado: (2019)